Eosinophilic cellulitis in response to BNT162b2 COVID‐19 vaccination
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Dermatology"
DOI: 10.1111/pde.15019
Abstract: A 12‐year‐old boy presented with a 2‐week history of persistent pruritic edematous plaques one day after he received the first dose of the BNT162b2 COVID‐19 mRNA vaccine. A skin biopsy showed urticarial dermatitis with tissue… read more here.
Keywords: bnt162b2 covid; cellulitis response; eosinophilic cellulitis;
Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.
Sign Up to like & getrecommendations! Published in 2023 at "Pediatrics"
DOI: 10.1542/peds.2022-060894
Abstract: OBJECTIVES We assessed BNT162b2 vaccine effectiveness (VE) against mild to moderate and severe coronavirus disease 2019 (COVID-19) in children and adolescents through the Omicron BA.4/BA.5 period. METHODS Using VISION Network records from April 2021 to… read more here.
Keywords: bnt162b2 covid; effectiveness bnt162b2; waning 150; 150 days ... See more keywords
Psoriatic arthritis flare-up after a second dose of BNT162b2 COVID-19 mRNA vaccine
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2022.4285
Abstract: EJD, vol. 32, n◦ 3, May-June 2022 escape mechanism in SS [7]. Furthermore, the receptor for CCL3 and CCR4 is found on tumour cells and regulatory T cells and is particularly involved in the development… read more here.
Keywords: bnt162b2 covid; second dose; dose bnt162b2; psoriatic arthritis ... See more keywords